ABC | Volume 114, Nº4, April 2020

Original Article Albuquerque et al. Ser49Gly Polymorphism in heart failure Arq Bras Cardiol. 2020; 114(4):613-615 13. Wang L, Lu L, Zhang F, ChenQ, ShenW. Polymorphisms of β -adrenoceptor and natriuretic peptide receptor genes influence the susceptibility to and the severity of idiopathic dilated cardiomyopathy in a Chinese cohort. J Card Fail. 2010;16(1):36-44. 14. Fiuzat M, Neely ML, Starr AZ, Kraus WE, Felker MG, Donahue M, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTIONDNA substudy. Eur J Heart Fail. 2013;15(3):258-66. 15. LiggettSB,Mialet-Perez J,Thaneemit-ChenS,WeberSA,GreeneSM,Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc National Acad Sci USA. 2006;103(30):11288-93. 16. Pereira SB, VellosoMW, Chermont S, QuintãoMM, Nunes Abdhala R, Giro C, et al. β -adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Mol Med Rep. 2013;7(1):259-65. 17. MagnussonY,LevinMC,EggertsenR,NyströmE,MobiniR,SchaufelbergerM,et al.Ser49Glyofbeta1-adrenergicreceptorisassociatedwitheffectivebeta-blocker dose indilatedcardiomyopathy.ClinPharmacolTher.2005;78(3):221-31. 18. Mangini S, Silveira F, Silva C, Grativvol P, da Seguro L, Ferreira S, et al. Decompensated heart failure in the emergency department of acardiology hospital. Arq Bras Cardiol. 2008;90(6):400-6. 19. Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of β 1-adrenoceptor: identification and rapid screening assay. Lancet.1999;353(9156):897. 20. SalantiG,AmountzaG,NtzaniEE, Ioannidis JP.Hardy–Weinbergequilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J HumGenet. 2005;13(7):840-8. 21. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007;93(4):476-82. 22. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34(19):1404-13. 23. Leineweber K, Frey UH, Tenderich G, Toliat MR, Zittermann A, Nürnberg P, et al. The Arg16Gly- β (2)-adrenoceptor single nucleotide polymorphism: exercise capacity and survival in patients with end-stage heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(4):357-65. 24. ForleoC,RestaN,SorrentinoS,GuidaP,ManghisiA,LucaV,etal. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med. 2004;117(7):451-8. 25. Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7B):44-8. 26. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail. 2009;15(3):191-8. 623